Recent Updates
Recently added Catalysts
RNXT Positive Sentiment

Revolutionizing Cancer Treatment: The Future of Localized Drug Delivery to Tumors with CEO Shaun Bagai

Key Takeaway: In a recent MedTech 101 episode, RenovoRx CEO Shaun Bagai discusses advancements in cancer treatment, particularly for pancreatic cancer. He highlights the company's localized therapy platform, which delivers chemotherapy directly to tumors, minimizing systemic side effects. The conversation emphasizes the importance of patient-centric innovation and the agility of startups in the medtech space. Bagai expresses optimism about the future of oncology and drug delivery systems.
Price reaction · baseline $0.8349 (2025-11-25T17:50:00.000Z) · hit during market hours · 1 other RNXT headline(s) in the window, move may be shared
day 0 close · peak
+3.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Innovative localized therapy platform for cancer treatment.
  • Direct delivery of chemotherapy reduces systemic side effects.
  • Technological advancements bring renewed hope for patients.
  • Strategic independence allows for agile development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
12.3%
average across 4 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
nab-paclitaxel
Phase 3 · Locally Advanced Pancreatic Cancer

Full Press Release Details

In this compelling episode of MedTech 101, host Rodney Moses sits down with RenovoRx CEO Shaun Bagai to explore the latest breakthroughs in cancer treatment. The conversation opens with a clear-eyed look at the challenges pancreatic cancer patients face, before diving into Shaun’s remarkable journey—from aspiring pre-med student to seasoned medtech leader—and the pivotal role engineering plays in redefining cancer care.
Rodney underscores the importance of pairing technological innovation with true patient-centric thinking, setting the tone for an insightful discussion on medtech’s ability to transform lives.
Shaun explains how RenovoRx is changing the treatment landscape through its patented localized therapy platform, designed to deliver chemotherapy directly to the tumor while reducing life-limiting systemic side effects. Their discussion highlights the development and impact of the RenovoCath catheter and the Trans-Arterial Micro-Perfusion (TAMP) system, technologies that enable precise, targeted drug delivery and bring renewed hope for improved outcomes.
Rodney and Shaun also touch on the contrast between the agility of startups and the slower pace of traditional medtech companies—using RenovoRx’s journey to a NASDAQ listing, without being acquired by a larger player, as a powerful example of strategic independence. The episode wraps with optimism about the future of oncology and the transformative potential of smarter drug-delivery systems.
Listen to the full podcast episode on Spotify

Frequently Asked Questions

What is RenovoRx's approach to cancer treatment?

RenovoRx utilizes a localized therapy platform to deliver chemotherapy directly to tumors.

How does localized drug delivery benefit patients?

It reduces life-limiting systemic side effects associated with traditional chemotherapy.

What technologies does RenovoRx use?

They use the RenovoCath catheter and Trans-Arterial Micro-Perfusion system for targeted delivery.

What is the significance of Shaun Bagai's leadership?

His journey illustrates the impact of strategic independence in medtech innovation.

Where can I listen to the full podcast episode?

The full episode is available on Spotify.

Last updated: Nov 25, 2025